Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society
|
June 26, 2020
Epidemiological characteristics and clinical analyses of chronic cutaneous wounds of inpatients in China: Prevention and control
Biao Cheng, Yufeng Jiang, Xiaobing Fu, et al.
Diabetes, Obesity & Metabolism
|
August 22, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)
Leili Gao, Linong Ji, Xin Yan, et al.
Current Medical Research and Opinion
|
September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
Linong Ji, Leili Gao, Zhifeng Cheng, et al.
Diabetes, Obesity & Metabolism
|
September 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy
Linong Ji, Jinmiao Lu, Leili Gao, et al.
Annals of Internal Medicine
|
June 29, 2026
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial
Ming Liu, Zhifeng Cheng, Li Lu, et al.
Journal of Diabetes Investigation
|
November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study
Leili Gao, Zhifeng Cheng, Guoqing Ma, et al.
Journal of Diabetes
|
April 7, 2024
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial
Lingding Xie, Jie Han, Zhifeng Cheng, et al.
Metabolism: Clinical and Experimental
|
March 16, 2026
Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial
Liming Chen, Xiaolin Dong, Qiumei Zhang, et al.
The International Journal of Lower Extremity Wounds
|
January 10, 2015
Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China
Yufeng Jiang, Xingwu Ran, Lijing Jia, et al.
Diabetes, Obesity & Metabolism
|
January 3, 2023
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial
Linong Ji, Xiaozhen Jiang, Qingshun Hao, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society
|
June 26, 2020
Epidemiological characteristics and clinical analyses of chronic cutaneous wounds of inpatients in China: Prevention and control
Biao Cheng, Yufeng Jiang, Xiaobing Fu, et al.
Diabetes, Obesity & Metabolism
|
August 22, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)
Leili Gao, Linong Ji, Xin Yan, et al.
Current Medical Research and Opinion
|
September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
Linong Ji, Leili Gao, Zhifeng Cheng, et al.
Diabetes, Obesity & Metabolism
|
September 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy
Linong Ji, Jinmiao Lu, Leili Gao, et al.
Annals of Internal Medicine
|
June 29, 2026
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial
Ming Liu, Zhifeng Cheng, Li Lu, et al.
Journal of Diabetes Investigation
|
November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study
Leili Gao, Zhifeng Cheng, Guoqing Ma, et al.
Journal of Diabetes
|
April 7, 2024
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial
Lingding Xie, Jie Han, Zhifeng Cheng, et al.
Metabolism: Clinical and Experimental
|
March 16, 2026
Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial
Liming Chen, Xiaolin Dong, Qiumei Zhang, et al.
The International Journal of Lower Extremity Wounds
|
January 10, 2015
Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China
Yufeng Jiang, Xingwu Ran, Lijing Jia, et al.
Diabetes, Obesity & Metabolism
|
January 3, 2023
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial
Linong Ji, Xiaozhen Jiang, Qingshun Hao, et al.
Page
of 8